CL2022001951A1 - Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a - Google Patents
Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora aInfo
- Publication number
- CL2022001951A1 CL2022001951A1 CL2022001951A CL2022001951A CL2022001951A1 CL 2022001951 A1 CL2022001951 A1 CL 2022001951A1 CL 2022001951 A CL2022001951 A CL 2022001951A CL 2022001951 A CL2022001951 A CL 2022001951A CL 2022001951 A1 CL2022001951 A1 CL 2022001951A1
- Authority
- CL
- Chile
- Prior art keywords
- aurora
- heterocyclic compounds
- compounds useful
- selective inhibitors
- novel heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020073786 | 2020-01-22 | ||
| CN2020076159 | 2020-02-21 | ||
| CN2020085922 | 2020-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001951A1 true CL2022001951A1 (es) | 2023-04-14 |
Family
ID=76993163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001951A CL2022001951A1 (es) | 2020-01-22 | 2022-07-19 | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20230128198A1 (https=) |
| EP (1) | EP4093736A4 (https=) |
| JP (1) | JP7688646B2 (https=) |
| KR (1) | KR102828343B1 (https=) |
| CN (2) | CN114423751B (https=) |
| AU (1) | AU2021209744B2 (https=) |
| CL (1) | CL2022001951A1 (https=) |
| CO (1) | CO2022010878A2 (https=) |
| IL (1) | IL294247B2 (https=) |
| MX (1) | MX2022009059A (https=) |
| PH (1) | PH12022551858A1 (https=) |
| TW (1) | TWI785474B (https=) |
| WO (1) | WO2021147974A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823974A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche AG | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CN112239465A (zh) | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
| JP2025506772A (ja) * | 2022-02-23 | 2025-03-13 | リペア セラピューティクス インコーポレイテッド | ポロ様キナーゼ４（ｐｌｋ４）阻害剤、医薬組成物、ならびにそれらを調製する方法、及びそれらの使用方法 |
| CN115057811B (zh) * | 2022-05-26 | 2024-06-14 | 安庆朗坤药业有限公司 | 一种2-溴甲基-3,5-二氟吡啶的制备方法 |
| CN115322143B (zh) * | 2022-07-21 | 2023-07-14 | 安徽德诺医药股份有限公司 | 一种4-哌啶甲酸叔丁酯盐酸盐的制备方法 |
| WO2024230647A1 (zh) * | 2023-05-05 | 2024-11-14 | 苏州信诺维医药科技股份有限公司 | 杂环类化合物、其药物组合物和其应用 |
| CN116903587B (zh) * | 2023-06-01 | 2024-03-22 | 三峡大学 | 一种角鲨烯环氧酶抑制剂及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008081492A (ja) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| EP2254888B1 (en) * | 2008-02-22 | 2014-12-24 | Msd K.K. | Novel aminopyridine derivatives having aurora a selective inhibitory action |
| TWI485146B (zh) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
| TWI693218B (zh) * | 2014-11-14 | 2020-05-11 | 美商美國禮來大藥廠 | 極光ａ激酶抑制劑 |
| MX2021006011A (es) * | 2018-11-30 | 2021-09-21 | Lilly Co Eli | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. |
| CN112239465A (zh) * | 2019-07-16 | 2021-01-19 | 微境生物医药科技(上海)有限公司 | 极光激酶抑制剂及其用途 |
| CN112898292A (zh) * | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | 新型极光激酶抑制剂及其用途 |
-
2021
- 2021-01-21 TW TW110102296A patent/TWI785474B/zh active
- 2021-01-22 WO PCT/CN2021/073169 patent/WO2021147974A1/en not_active Ceased
- 2021-01-22 MX MX2022009059A patent/MX2022009059A/es unknown
- 2021-01-22 CN CN202180003823.8A patent/CN114423751B/zh active Active
- 2021-01-22 CN CN202310353468.8A patent/CN116354936A/zh active Pending
- 2021-01-22 JP JP2022544153A patent/JP7688646B2/ja active Active
- 2021-01-22 AU AU2021209744A patent/AU2021209744B2/en active Active
- 2021-01-22 PH PH1/2022/551858A patent/PH12022551858A1/en unknown
- 2021-01-22 IL IL294247A patent/IL294247B2/en unknown
- 2021-01-22 US US17/794,641 patent/US20230128198A1/en not_active Abandoned
- 2021-01-22 KR KR1020227021336A patent/KR102828343B1/ko active Active
- 2021-01-22 EP EP21743926.4A patent/EP4093736A4/en active Pending
- 2021-09-24 US US17/484,456 patent/US11384066B1/en active Active
-
2022
- 2022-07-19 CL CL2022001951A patent/CL2022001951A1/es unknown
- 2022-08-02 CO CONC2022/0010878A patent/CO2022010878A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423751A (zh) | 2022-04-29 |
| JP2023513419A (ja) | 2023-03-31 |
| CO2022010878A2 (es) | 2022-08-19 |
| CA3161268A1 (en) | 2021-07-29 |
| CN116354936A (zh) | 2023-06-30 |
| IL294247A (en) | 2022-08-01 |
| US11384066B1 (en) | 2022-07-12 |
| KR20220131514A (ko) | 2022-09-28 |
| MX2022009059A (es) | 2022-08-15 |
| JP7688646B2 (ja) | 2025-06-04 |
| TW202140449A (zh) | 2021-11-01 |
| EP4093736A4 (en) | 2024-01-10 |
| WO2021147974A1 (en) | 2021-07-29 |
| IL294247B1 (en) | 2025-07-01 |
| IL294247B2 (en) | 2025-11-01 |
| US20230128198A1 (en) | 2023-04-27 |
| AU2021209744B2 (en) | 2023-08-31 |
| TWI785474B (zh) | 2022-12-01 |
| AU2021209744A1 (en) | 2022-07-07 |
| EP4093736A1 (en) | 2022-11-30 |
| PH12022551858A1 (en) | 2024-01-03 |
| CN114423751B (zh) | 2023-04-21 |
| KR102828343B1 (ko) | 2025-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001951A1 (es) | Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a | |
| DOP2025000245A (es) | Inhibidores de kras | |
| MX2024003721A (es) | Inhibidores alostericos de cromenona de la fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| DOP2023000245A (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| NI201800093A (es) | Inhibidores de mcl1 macrocíclicos para tratar el cáncer | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CR20110224A (es) | Pirazolopirimidina inhibidor jak compuestos y metodos | |
| CO6300939A2 (es) | Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada | |
| DOP2003000613A (es) | Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors) | |
| GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| UY39150A (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| MX2024008629A (es) | Derivados del azaindol y su uso como inhibidores de la erk-cinasa. | |
| MX2023013987A (es) | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. | |
| DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
| MX2023014466A (es) | Derivados de piridopirimidina útiles como inhibidores de cinasa wee1. | |
| CL2025000445A1 (es) | Inhibidores de kif18a y usos de estos | |
| CL2025002615A1 (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| MX2024007929A (es) | Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. | |
| ECSP23091202A (es) | Moduladores de trex1 | |
| CR20210661A (es) | Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos | |
| DOP2012000056A (es) | Agente terapeutico para trastornos de ansiedad | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| AR128426A1 (es) | Compuestos heterocíclicos y métodos de uso | |
| AR132459A1 (es) | Inhibidores de kras de pirrolidina |